EAST NORRITON, Pa., Jan. 30 Tengion Inc., a clinical stageregenerative medicine company focused on the development of neo-organs andneo-vessels, announced today that Steven Nichtberger, M.D., President andChief Executive Officer, will be presenting at the Merrill Lynch GlobalPharmaceutical, Biotechnology and Medical Device Conference on Tuesday,February 5, 2008 at 9:20 a.m. EST. The conference will be held at the GrandHyatt Hotel in New York City.
Tengion, a clinical stage biotechnology company, has pioneered theAutologous Organ Regeneration Platform(TM) that catalyzes the body's innateability to regenerate. Tengion's neo-organs and neo-tissues in development,such as bladders and vessels, combine biocompatible materials and a patient'sown (autologous) cells to regenerate diseased and failing organs and tissues.Tengion's product candidates have the potential to cure -- rather than treat-- organ and tissue failure, enabling people to lead healthier lives withoutdonor transplants or the side effects of related therapies. For moreinformation on the company and current clinical trials, visit Tengion onlineat: http://www.tengion.com.
SOURCE Tengion Inc.